Total Voting Rights
10 May, 2013
Sareum Notified of Grant Award
24 April, 2013
Sareum and SRI International Announce Co-development Agreement
22 April, 2013
Issue of Equity
25 March, 2013
Adviser Change of Name
19 March, 2013
Research Update
18 February, 2013
Half-Yearly Report
18 February, 2013
Director Declaration
11 February, 2013
US Patent Grant
07 February, 2013
Notice of Results
04 February, 2013
Total Voting Rights
31 December, 2012
Result of AGM
12 December, 2012
Annual General Meeting Statement
12 December, 2012
Issue of Equity
05 December, 2012
Notice of AGM
14 November, 2012
Availability of Report and Accounts
13 November, 2012
Statement re Share Price Movement
06 November, 2012
Final Results
03 October, 2012
Financing
10 September, 2012
Statement re Share Price Movement
07 August, 2012
Trading Update
19 July, 2012
Total Voting Rights
29 June, 2012
Placing
07 June, 2012
Placing
06 June, 2012
Previous releases
2013 2012 2011 2010 2009 2008 2007 2006 2005 2004
News feed
requires RSS news reader
30 January 2012
Sareum Holdings plc
("Sareum" or "the Company")
Notice of Results
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery business, will announce its Interim Results for the six months ended 31 December 2011 on Monday, 27 February 2012.
Along with its Interim Results, the Company will also provide a research update on its cancer and auto-immune disease drug programmes.
Enquiries:
|
Sareum Holdings plc |
|
|
Tim Mitchell |
01223 497 700 |
|
Merchant Securities Limited (Nomad) |
|
|
Simon Clements |
020 7628 2200 |
|
Hybridan LLP (Broker) |
|
|
Claire Noyce / Tim Goodman / Deepak Reddy |
020 7947 4350 |
|
The Communications Portfolio (Media enquiries) Ariane Comstive / Caolan Mahon ariane.comstive@communications-portfolio.co.uk |
020 7536 2028 / 2029 |
About Sareum Holdings plc
Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum's Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.
SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR. For further information, please visit www.sareum.co.uk
Requires MS Word
Requires Adobe Acrobat Reader